Cost-effectiveness of clopidogrel: Seeing through the smoke

Medical Decision Making

Volumn 28, Issue 6, 2008, Pages 803-809

  Goldman, Lee ^a,b   Gaspoz, Jean Michel ^b,c  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antiplatelet drugs; Cost effectiveness; Models; Pharmaceutical support

Indexed keywords

CLOPIDOGREL; METOPROLOL;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE POLICY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MEDLINE; NOTE; PARSIMONY ANALYSIS; PHARMACEUTICAL CARE; SECONDARY PREVENTION; SYSTEMATIC REVIEW;

CORONARY DISEASE; COST-BENEFIT ANALYSIS; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; TICLOPIDINE;

EID: 57049169848     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X08318467     Document Type: Note

References (43)

1. Karnon J., Brennan A., Akehurst R. A critique and impact analysis of decision modeling assumptions. Med Dec Making. 2007 ; 27: 491-9.
2. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002 ; 346: 1800-6.
3. Eddy DM, Schlessinger L., Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005 ; 143: 251-64.
4. Eddy DM Accuracy versus transparency in pharmacoeconomic modeling: finding the right balance. Pharmacoeconomics. 2006 ; 24: 837-44.
5. Bhatt DL, Fox KAA, Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 ; 354: 1706-17.
6. Drummond MF, Barbieri M., Wong JB Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference ? Med Decis Making. 2005 ; 25: 520-33.
7. Russel LB Comparing model structures in cost-effectiveness analysis. Med Decis Making. 2005 ; 25: 485-6.
8. McCabe C. Guidance on good practice in cost-effectiveness modeling: is more needed ? Med Decis Making. 2007 ; 27: 350-1.
9. Yusuf S., Zhao F., Mehta SR, et al, for the Clopidogrel in Unstable Angina to Prevent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published corrections appear in N Engl J Med. 2001 ; 345: 1716 and N Engl J Med. 2001 ; 345: 1506 ]. N Engl J Med. 2001 ; 345: 494-502.
10. Gaspoz JM, Coxson PG, Goldman L., et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease [corrected version published on NEJM Web site on 6 February 2003]. N Engl J Med. 2003 ; 346: 1800-6.
11. DeLemos JA, McGuire DK Aspirin, clopidogrel, or both for secondary prevention of coronary disease [letter to the editor]. N Engl J Med. 2003 ; 348: 561.
12. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996 ; 348: 1329-39.
13. COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet. 2005 ; 366: 1607-21.
14. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 ; 352: 1179-89.
15. Lagakos SW The challenge of subgroup analyses: reporting without distorting. N Engl J Med. 2006 ; 354: 1667-9.
16. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 ; 288: 2411-20.
17. Mehta SR, Yusuf S., Peters RJ, et al, for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI CURE study. Lancet. 2001 ; 358: 527-33.
18. Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the ''Emperor's New Clothes'' revisited. Eur Heart J. 2004 ; 25: 720-2.
19. Khot UN, Nissen SE Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance. J Am Coll Cardiol. 2002 ; 40: 218-9.
20. Helton TJ, Bavry AA, Kumbhani DH, et al. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease. Am J Cardiovasc Drugs. 2007 ; 7: 289-97.
21. Keller TT, Squizzato A., Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev. 2007 ;( 3 ):CD005158.
22. Brüggenjürgen B., Lindgren P., Ehlken B., et al. Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. Eur J Health Econ. 2007 ; 8: 51-7.
23. Lindgren P., Jönsson B., Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the cure trial. J Intern Med. 2004 ; 255: 562-70.
24. Weintraub WS, Mahoney EM, Lamy A., et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol. 2005 ; 45: 838-45.
25. Karnon J., Bakhai A., Brennan A., et al. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK. Int J Cardiol. 2006 ; 109: 307-16.
26. Badia X., Bueno H., Gonzalez Juanatey JR, et al. Short- and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain. Rev Esp Cardiol. 2005 ; 58: 1385-95.
27. Lindgren P., Stenestrand U., Malmberg K., et al. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin Ther. 2005 ; 27: 100-10.
28. Mahoney EM, Mehta S., Yuan Y., et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J. 2006 ; 151: 219-27.
29. Beinart SC, Kolm P., Veledar E., et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention. J Am Coll Cardiol. 2005 ; 46: 761-9.
30. Ringborg A., Lindgren P., Jönsson B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention. Eur J Health Econ. 2005 ; 6: 354-62.
31. Karnon J., Brennan A., Pandor A., et al. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr Med Res Opin. 2005 ; 21: 101-12.
32. Berger K., Hessel F., Kreuzer J., et al. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Curr Med Res Opin. 2008 ; 24: 267-74.
33. Berg J., Lindgren P., Spiesser J., et al. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials. Clin Ther. 2007 ; 29 ; 1184-1202.
34. Heeg BMS, Peters RJG, Botteman M., et al. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention. Pharmacoeconomics. 2007 ; 25: 769-82.
35. Kolm P., Yuan Y., Veledar E., et al. Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. Can J Cardiol. 2007 ; 23: 1037-42.
36. Cowper PA, Udayakumar K., Sketch MH, et al. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. J Am Coll Cardiol. 2005 ; 45: 369-76.
37. Latour-Perez J., Navarro-Ruiz A., Ridao-Lopez M., et al. Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. Value Health. 2004 ; 7: 52-60.
38. Schleinitz MD, Heidenreich PA A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med. 2005 ; 142: 251-60.
39. Robinson M., Palmer S., Sculpher M., et al. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modeling. Health Technol Assess. 2005 ; 9 (27). 1-158.
40. Schleinitz MD, Weiss JP, Owens DK Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med. 2004 ; 116: 797-806.
41. Matchar DB, Samsa GP, Liu S. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty. Value Health. 2005 ; 8: 572-80.
42. Cheng JW Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease. J Managed Care Pharm. 2007 ; 13: 326-36.
43. Heeg B., Damen J., Van Hout B. Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective. Pharmacoeconomics. 2007 ; 25 ; 1063-82.